Opinion|Videos|December 19, 2023
Retrospective Study on Bortezomib Dosing in NDMM
Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5